UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

Clinical trial NCT06092047 · RECRUITING

Trial details

NCT number: NCT06092047
Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

CD19-positive Relapsed or Refractory B-cell Malignancies

Start date: 2023-10-01
Primary completion: 2026-07-01
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.